Biolight

Quarterly report January - March 31, 2003

Mon, May 05, 2003 17:12 CET

Biolight International AB (publ) Quarterly report January 1 - March 31, 2003 · Sales during the first quarter amounted to SEK 457 T (513). · The clinical acceptance within the wound care area has been further strengthened. The geriatric clinic at Östra Sjukhuset, Göteborg, has purchased Biolight® for their treatment of chronic wounds. Company focus in 2003 This year, the company will focus its resources on continuing to establish Biolight® Wound Care in Sweden, and Biolight® Dental Care in Sweden, Germany and Italy. Sales - Q1:2003 Sales during the first quarter amounted to SEK 457 T (513).

Annual report 2002

Mon, Apr 07, 2003 13:00 CET

ANNUAL REPORT THE FINANCIAL YEAR JANUARY 1, 2002 - DECEMBER 31, 2002 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/05/16/20030516BIT00330/wkr0001.PDF Annual Report 2002

Annual Earnings figures for 2002

Thu, Feb 20, 2003 11:35 CET

Press release of annual earnings figures for the financial year 2002 The board of directors of Biolight International AB presents the annual earnings figures for 2002. The year in brief: The treatment results and treatment method have now been so well documented that operations in 2002 have changed focus from clinical trials and technology & method development to market penetration and commercialisation. During the year, the company has begun its commercialisation of Biolight® by entering into cooperation with distributors within the business area Dental Care, and within the business area

Semi-annual report January 1 - June 30, 2002

Thu, Aug 29, 2002 12:49 CET

Biolight International AB (publ) Semi-annual report January 1 - June 30, 2002 Second quarter 2002 · Sales during the first six months amounted to SEK 1,212 T (325). Sales during the second quarter amounted to SEK 699 T (211). · Very positive outcome of our practical wound care test within the home medical care service (Hemsjukvården) in western Göteborg, Sweden. As a result of this positive outcome, Biolight has become a part of the regular treatment of chronic wounds. The company has signed a 2- year agreement regarding treatment with Biolight. · The Company has also signed a similar 1-

First commercial order from National Health

Mon, Jun 24, 2002 12:03 CET

First commercial order from National Health Biolight has signed its first agreement with the home medical care service in western Göteborg, Sweden, regarding treatment of patients with chronic wounds. The Biolight® treatment has been evaluated during spring 2002. Six selected patients with chronic wounds have received treatment for two months. The patients with chronic wounds (6 months - 5 years) have all demonstrated significant healing after treatment with Biolight®, and two wounds have healed completely during this test period. The treatment has been administered by home care nurses 2 -

Quarterly report January 1-March 31, 2002

Thu, Apr 25, 2002 13:00 CET

Biolight International AB (publ) Quarterly report January 1 - March 31, 2002 ·Sales during the first quarter amounted to SEK 513 T (SEK 114T). ·The company has floated a new share issue. This issue, directed towards a number of institutional investors, provided the company with SEK 25 million before issue expenses. ·A preliminary report of the study on pain relief in connection with extraction (surgery) of wisdom teeth, shows that the patients treated with Biolight® experienced 40% less pain and consumed 50% less pain-killers on the day following surgery. The results are statistically

Press release of annual earnings figures for the financial year 2001

Fri, Feb 22, 2002 08:58 CET

Press release of annual earnings figures for the financial year 2001 The board of directors of Biolight International AB presents annual earnings figures for the financial year 2001. Important events during the year: · A phase III study on decubitus ulcers has been finalised during the year. The effect shown is considerable and statistically significant. The study shows that time to healing within the group treated with active equipment was reduced by 36 % as compared to the placebo-treated group. The result is a decisive breakthrough for Biolight Wound Care. · Important results regarding

Biolight prepares distribution in the Far East

Wed, Jan 30, 2002 09:26 CET

Press release from Biolight International AB Danderyd, January 28, 2002 Biolight prepares distribution in the Far East The company has reached a distribution agreement regarding Dental Care with C&N Med-Dent CO., Ltd in Taiwan. The company has also signed a "Letter of Intent" with Denics International Co., Ltd. in Japan, regarding registration and distribution for Dental Care. C&N Med-Dent CO., Ltd., Taiwan C&N Med-Dent has existed for 8 years in the Taiwan market, has 38 employees and current annual sales of about USD 5,5 million. C&N is organised into two divisions, Dental and Medical. C&

FDA approval - 510(k) - for Biolight

Wed, Jan 23, 2002 15:40 CET

FDA approval - 510(k) - for Biolight The company has gained FDA approval - 510(k) - for Physiotherapeutic Care. This approval allows the company to market and sell its equipment (PCD) and treatment programs for prevention and rehabilitation of injuries in the locomotor apparatus (locomotorium) in the American market. Christer Wallin, President of Biolight International AB, says: "We are very excited about being able to present the market with an approval regarding the American market. "Wellness" is one of the most rapidly growing industries in the USA, with annual sales amounting to about

Biolight reaches research agreement with KI

Fri, Jan 11, 2002 12:48 CET

Biolight reaches research agreement with KI Biolight has reached a preliminary agreement with the Karolinska Institutet (KI) regarding research to optimise and fine-tune, by means of micro array technology (Affymetrix), the various treatment programs currently used by the company. Attempts will also be made to map out the signal paths in the cells initiated through Biolight®. Professor Jan-Åke Gustafsson, KI, says: "Micro array technology (Affymetrix) has been used to study the gene expression in fibroblasts (connective tissue cells) after treatment with Biolight®, treatment that has

Biolight signs agreement with one of Europe's leading dental companies

Thu, Nov 22, 2001 14:51 CET

Biolight signs agreement with one of Europe's leading dental companies Biolight has signed an agreement regarding its distribution in Finland with Plandent Oyj. Plandent is a member of the Planmeca group, with a turnover of approximately SEK 2.9 billion (EUR 300 million) and about 1,300 employees. The Planmeca group sells in more than 80 countries. Plandent has subsidiaries and distribution companies in Scandinavia, Great Britain, Germany, Russia and the Baltic States. "Plandent Oyj has started marketing and sales activities for Biolight in Finland. We work in close co-operation with the

Biolight signs agreement with the Praktikertjänst Group

Mon, Oct 29, 2001 09:57 CET

Biolight signs agreement with the Praktikertjänst Group On this day Biolight has entered into an agreement with the Praktikertjänst Group. It is very positive for Biolight to be able to gain rapid acceptance for its proven treatment methodology and in that way be able to speed up its market penetration in Sweden. The Praktikertjänst Group has a thorough purchasing procedure with strong requirements when it comes to clinical studies, ISO certification and CE approval. Ola Kroon, who is responsible for the agreement at the Praktikertjänst Group, comments: "We enter into co-operative contracts

Biolight® effects shown using molecular biology technology.

Fri, Oct 26, 2001 11:12 CET

Biolight® effects shown using molecular biology technology. New research results from the Karolinska Institutet show that effects of treatment with Biolight can now be measured using molecular biology technology. The results indicate that six hours after treatment a significant increase in the activities of a number of genes could be observed, including genes coded for growth factors and collagen. After several years of clinical studies Biolight International AB is able to provide significant results on wound healing and oral inflammations. Aiming to gain knowledge about what it is that

Biolight® effects shown using molecular biology technology

Thu, Oct 25, 2001 13:00 CET

Biolight® effects shown using molecular biology technology. New research results from the Karolinska Institutet show that effects of treatment with Biolight can now be measured using molecular biology technology. The results indicate that six hours after treatment a significant increase in the activities of a number of genes could be observed, including genes coded for growth factors and collagen. After several years of clinical studies Biolight International AB is able to provide significant results on wound healing and oral inflammations. Aiming to gain knowledge about what it is that

International agreement for Biolight

Mon, Oct 15, 2001 15:43 CET

International agreement for Biolight Biolight has reached an agreement with the British dental company TryCare Ltd., granting TryCare exclusive rights to sell Biolight Dental Care in Great Britain. Periodontitis (loosening of the teeth) is a very common disease leading to considerable treatment costs for the public health service every year. Biolight's effective and clinically verified method may add a new dimension to public dental care, according to TryCare, which is one of the new market-oriented distribution companies within dental care products in the British market. This agreement is

Semi-annual report January 1 - June 30, 2001

Fri, Aug 31, 2001 12:25 CET

Biolight International AB (publ) Semi-annual report January 1 - June 30, 2001 * The company has signed a blanket agreement with TryCare Limited regarding the distribution within Dental Care in the UK. Discussions are also ongoing with distributors in other markets within the business area Dental Care. * A controlled study on decubitus ulcers has been finalised during this period. The effect shown is considerable and statistically significant. The result is a decisive breakthrough for Biolight® Wound Care. * A market test has been conducted by a group of private dentists and dental

Decision on authorisation for the Board of Biolight International AB, July 9, 2001.

Wed, Jul 11, 2001 10:29 CET

Decision on authorisation for the Board of Biolight International AB, July 9, 2001. The extraordinary general meeting of Biolight International AB has today resolved to authorise the board to decide about new issues, at one or several occasions up to the next annual general meeting, leading to a total maximum issue of 20,000,000 shares of series A or B. New issues, within the limits mentioned above, may be floated both as issues of shares and as convertible debt instruments or debt instruments with subscription warrants for new shares. At such issues, payment in kind should be allowed. An

Ludmila Engquist is our guest during" Idrottsgolfen" at St. Jörgen's Golf Club in Gothenburg on 6 July

Wed, Jun 27, 2001 13:00 CET

Ludmila Engquist is our guest during "Idrottsgolfen" at St. Jörgen's Golf Club in Gothenburg on 6 July Ludmila Engquist, the bandy player Per Fosshaug and NHL pro Niclas Hävelid are 3 of almost 100 elite sportsmen to visit "Idrottsgolfen", a golf competition arranged by Mölndal's Table Tennis Club in co-operation with GolfEvent at the St Jörgen Golf Club in Gothenburg. Other participants from the sports elite of the world are NHL player Daniel Alfredsson, handball pro Magnus Wislander and the Olympic archery medallist Magnus Pettersson. International participants include the English

Extraordinary General Meeting of Biolight International AB (publ)

Tue, Jun 12, 2001 13:00 CET

Extraordinary General Meeting of Biolight International AB (publ) The shareholders of Biolight International AB (publ) are invited to attend an extraordinary general meeting held at 11 a.m. on Monday, July 9, 2001, at the company headquarters, Svärdvägen 15, Danderyd. Notice to attend Shareholders who wish to participate must: - be recorded in the shareholders' register kept by VPC AB (Swedish Securities Register Centre) no later than Friday, June 29, 2001, - and also notify the company no later than at 4 p.m. on Wednesday, July 4, 2001, by mail sent to Svärdvägen 15, SE-182 33 Danderyd,

Annual General Meeting of Biolight International AB, April 25, 2001

Thu, Apr 26, 2001 13:00 CET

Annual General Meeting of Biolight International AB, April 25, 2001 Biolight's Annual General Meeting decided in favour of all the propositions included in the notice to attend the general meeting. Scientific studies have confirmed the effectiveness of Biolight®, and Biolight International AB is now entering a more commercial phase. At Biolight's Annual General Meeting of April 25, 2001, the President, Christer Wallin made a presentation of the development of Biolight, including a demonstration of the new products for wound care, gingivitis (inflammation of the gums) and rehabilitation. The

Quarterly report January 1 - March 31, 2001

Mon, Apr 23, 2001 13:00 CET

Biolight International AB (publ) Quarterly report January 1 - March 31, 2001 · The wound healing study finalised during the first quarter is a decisive breakthrough for Biolight®. The established effect is considerable and statistically significant. · Biolight® PCD (Physiotherapeutic Care Device) - a new device for the treatment and rehabilitation of sports injuries - was approved for CE-marking in March, 2001. · The company filed a 510(k) application with the FDA in February 2001 for the area dental care. FDA desires to study the clinical documentation. · In January, a Technical Director,

Breakthrough for unique method in wound healing

Wed, Mar 28, 2001 13:00 CET

Breakthrough for unique method in wound healing Biolight has developed a unique method, which reduces the time to healing for chronic wounds. This has been confirmed through a recent study carried out in Sweden and Denmark. The study shows that the time to healing was reduced by 36%. The estimated number of chronic wounds, only in Sweden, is currently estimated to about 100,000, a figure which, considering the age structure, is expected to increase. Today at 12 a.m., the result of the study will be presented by Christer Wallin, the company's president, and Jan-Åke Gustafsson, chairman of

Press release of annual earnings figures for the financial year 2000

Fri, Feb 23, 2001 12:00 CET

Biolight International AB (publ) Press release of annual earnings figures for the financial year 2000 · Studies have been carried out within all the three business areas, Wound Care, Dental Care and Physiotherapeutic Care, and the results have been good. · In the completed phase III study, BL-034, on the healing of decubitus ulcers, grade 2, the last patient finished treatment on January 16, 2001. A statistical report is expected to be ready in March 2001. · A phase III study on patients with gingivitis (inflammation of the gums) was presented in June. The study shows a statistically